Why the study?
Does a Thrombelastograph (TEG) ecarin clotting time (ECT) assay improve correlation to bivalirudin plasma levels compared to a standard ACT assay in patients undergoing interventional cardiology procedures?
Does a Thrombelastograph (TEG) ecarin clotting time (ECT) assay improve correlation to bivalirudin plasma levels compared to a standard ACT assay in patients undergoing interventional cardiology procedures?
The TEG ECT assay demonstrates a significantly stronger correlation with bivalirudin plasma levels than the standard ACT assay, suggesting it may be more useful for monitoring anticoagulation during interventional procedures.
Answers are grounded in this paper and cite their sources.
TEG ECT may support better bivalirudin monitoring than ACT in procedures; hypothesis-generating and should not yet change practice.
Standard activated clotting time (ACT) tests have a poor correlation to bivalirudin levels, leading to uncertainty regarding adequate anticoagulation in percutaneous coronary intervention patients. We tested a Thrombelastograph (TEG) ecarin clotting time (ECT) assay for sensitivity to bivalirudin using blood from 80 patients undergoing interventional cardiology procedures with bivalirudin anticoagulation. This was compared to a standard Hemochron ACT assay using diatomaceous earth. With the TEG assay, the direct thrombin activator, ecarin, was used to initiate coagulation and measured as the reaction time. Plasma samples were evaluated for bivalirudin by a chromogenic assay at an independent hematological laboratory. Linear regression of the standard ACT versus bivalirudin level gave an r = 0.306 whereas the TEG ECT gave a much higher r2 = 0.746 (both P < 0.0001). The TEG ECT should prove more useful than the standard ACT for monitoring bivalirudin anticoagulation across the clinically therapeutic range.
No takes yet. Share an insight, caveat, or question.
Carroll et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: